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Abstract
In order to overcome restrictions imposed by activation (phosphorylation) mechanism of antiviral and antitumor nucleoside analogues
several prodrug approaches have been designed. Lipophilic pronucleotides are capable of intracellular delivery of monophosphates of
nucleoside analogues, thus circumventing the limitations of enzymic phosphorylation. One of the successful approaches employs lipophilic
amino acid ester (alanine) phenyl phosphoramidates as pronucleotides. This approach was applied to AIDS drugs such as AZT, d4T and
related analogues but also to nonclassical nucleoside analogues based on allenic and methylenecyclopropane structure. Antiviral effects of the
parent analogues were in many cases increased by conversion to phenyl phosphoralaninate (PPA) pronucleotides. Although cytotoxicity
increase frequently accompanies antiviral effects of these pronucleotides, a favorable selectivity index can be obtained by manipulation of the
parent structure as shown, e.g., for 2,6-diaminopurine methylenecyclopropane pronucleotide 15c. A lack of in vivo toxicity was demonstrated
for 2-amino-6-methoxypurine methylenecyclopropane pronucleotide 15e in mice. The PPA pronucleotides can overcome deficiency of
phosphorylating enzymes and offer favorable cross-resistance patterns when compared with other antiviral drugs. D 2002 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Nucleoside analogues have been a subject of numerous
studies as antiviral and anticancer agents [1]. In order to be
active they must be transformed to nucleotide metabolites by
viral and/or cellular enzymes. This activation process follows
the pathway utilized by natural nucleosides (Scheme 1). In
the first step, catalyzed by nucleoside kinases or phosphor-
ylases, nucleosides or their analogues 1 are phosphorylated to
give monophosphates 2. The latter are converted to diphos-
phates 3 by the action of nucleotide kinases. In the next step,
they are further processed to triphosphates 4 with the aid of
nucleotide diphosphate kinases. Triphosphates of nucleoside
analogues 4 then compete with their natural counterparts for
DNA or RNA polymerases. They either act as terminators of
growing polynucleotide chain or get incorporated into the
chain modifying thus the properties of the polymer. Selec-
tivity of the antiviral effect is then achieved by a differential
inhibition of viral and cellular polymerases by the corre-
sponding nucleoside triphosphates. In this respect, the latter
analogues are the actual therapeutic agents whereas parent
nucleosides can be considered as prodrugs of triphosphates.
It is then clear that intracellular introduction of nucleoside
analogues as phosphorylated metabolites could circumvent
difficulties associated with the use of nonphosphorylated
analogues and even activate inactive or less active com-
pounds. Such an approach obviates the crucial [2] first
phosphorylation step (Scheme 1) and delivers the mono-
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phosphate 2 into the cells. However, polarity (hydrophilicity)
and a ready degradation with phosphatases makes the use of
free nucleotide analogues 2 impractical. Therefore, much of
the recent effort has been focussed on finding suitable
prodrugs of monophosphates of nucleoside analogues (pro-
nucleotides). It is clear that requirements for such pronucleo-
tides include (i) resistance to degradation by phosphatases,
(ii) capability of penetrating the cellular membrane and (iii)
generation of the requisite nucleotide analogues 2 inside the
cell.
Three groups of pronucleotides, each with a different
mechanism of action, have gained prominence as antiviral
agents effective primarily against HIV (Scheme 2). The
S-acylthioethylphosphate (SATE) pronucleotides 5 elabo-
rated by Perigaud et al. [3], the phosphoramidates derived
from amino acids introduced by McGuigan et al. [4] and,
finally, cyclosaligenyl (cycloSal) pronucleotides 6 designed
and studied byMeier [5]. In the case of amino acid phosphor-
amidates, the studies have been largely focussed on phenyl
phosphoralaninates (PPA) 7 of anti-HIV agents zidovudine
(AZT) and stavudine (d4T). Extensive structure–activity
relationship studies [4,6–9] indicated that a combination of
alanine ester amidate and phenyl phosphate provides for the
most effective agents. Consequently, PPA triesters have been
used by several groups of investigators as antiviral pronu-
cleotides [10–15] and potential antitumor agents [16,17]. In
stereochemical terms, only SATE pronucleotides do not
contain a chiral phosphorus atom but both cycloSal and
amidate prodrugs 6 and 7 (alanine ester has an L-con-
figuration) derived from natural (D) nucleosides are mixtures
of two diastereoisomers.
The pronucleotide approach has been a subject of several
excellent reviews [3,5,18]. Therefore, this contribution will
focus on subjects not discussed in detail therein and, in
particular, PPA pronucleotides.
2. Synthesis
The synthesis of PPA triesters is shown for stavudine
(d4T) pronucleotide 8 [4,19] in Scheme 3. d4T (9) is
phosphorylated by reagent 10 in the presence of N-methyl-
imidazole as a base to give directly pronucleotide 8. Tetrahy-
drofuran (THF) is a suitable solvent. For less soluble
nucleoside analogues pyridine can be used [13]. Alternately,
tert-butylmagnesium chloride was also employed as a base
[20,21]. Starting analogues containing thymine (like AZT),
uracil or adenine moiety are phosphorylated without forma-
Scheme 1. Activation of nucleoside analogues.
Scheme 2. Pronucleotide approach.
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tion of a significant amounts of side-products (phosphoryla-
tion of the heterocyclic portion). For more reactive bases
(hypoxanthine, guanine, 2,6-diaminopurine), a prolonged
treatment of the crude product with acid (80% acetic acid)
is mandatory to remove products of concommitant phospho-
rylation of the nucleic acid base [11–13]. Alternately, and this
could be of advantage for nucleoside analogues with limited
acid stability, the guanine moiety was protected before
phosphorylation with anN2-dimethylaminomethylene group,
which was then removed by treatment with propanol [22].
Also, no phosphorylation of the cytosine ring using tert-
butylmagnesium chloride as a base was reported [20].
3. Antiviral activity of PPA triesters with an intact or
modified furanose ring
These studies have been focussed on PPA pronucleotides
of AIDS drugs zidovudine (AZT), stavudine (d4T) and
lamivudine (3TC), anti-HIV agents ddA and d4A as well
as attempts at introducing anti-HIV activity into some less
potent or inactive nucleoside analogues (Table 1). The PPA
pronucleotides of d4T [23], ddA [24] and d4A [21,24] have
an improved potency over the parent analogues against both
HIV-1 and HIV-2. However, this was not the case of AZT
[23]. Both AZT-PPA and d4T-PPA [23] were more active in
thymidine kinase-deficient cells (CEM/TK ) than AZT or
d4T but the efficacy of pronucleotide d4TPPA surpassed
that of AZT-PPA. The results have indicated that the
respective monophosphates were successfully delivered into
the host cells. It then appears that the rate limiting step for
AZT is conversion of monophosphate 2 to diphosphate 3
(Scheme 1) whereas the first phosphorylation may be
decisive for d4T [23]. By contrast, 3TC-PPA lost most of
anti-HIV potency associated with 3TC but activity (EC50
f 0.02 AM) against hepatitis B virus (HBV) in Hep G2
2.2.15 cells was preserved [20]. As expected, in CEM-
TK  cells the anti-HIV activity pattern remained the same
but in cells deficient in deoxycytidine kinase (dCK), an
enzyme crucial for phosphorylation of 3TC, 3TC-PPA had
no effect. These data were interpreted in terms of differences
in monophosphate delivery in CEM vs. 2.2.15 cells. An
inactive analogue ddisoA was successfully activated by
conversion into PPA pronucleotide [10] but this approach
failed with araA [25].
The PPA pronucleotides were only rarely investigated
with viruses other than HIV or HBV. Recently, acyclovir
derivative, acyclovir phenyl phosphoralaninate (ACV-PPA),
was tested [22] against human cytomegalovirus (HCMV),
herpes simplex virus 2 (HSV-2) and varicella zoster virus
(VZV) with disappointing results. The potency against HSV-
2 was significantly inferior to ACVindicating possibly a poor
delivery into the infected host cells. The efficacy against
HCMV and VZV corresponded roughly to that of ACV.
More interesting results were obtained with phosphonate
analogues of PPA triesters of antiviral agents adefovir
(PMEA) and tenofovir (PMPA, Chart 1) [26]. In this case,
the parent phosphonates are already surrogates of mono-
phosphates capable of penetrating cellular membrane, and the
effect of more lipophilic ‘‘prophosphonate’’ is on delivery of
the phosphonate rather than obviating the first phosphoryla-
tion step (Scheme 1). Both prophosphonates surpass the
potency of PMEA and PMPA (Table 2). This is most likely
due to an increased penetration of cellular membrane relative
to negatively charged parent phosphonates [27]. Neverthe-
less, a significantly increased efficacy of prodrug 11b relative
to its lower homologue 11a is probably indicative of some
other important factors. A large-scale separation [28] of both
diastereoisomeric isopropyl alaninates 11c by chiral chroma-
Scheme 3. Synthesis of PPA pronucleotides.
Table 1
Comparison of Anti-HIV Activity of PPA pronucleotides and parent
nucleoside analogues
Compound EC50/CC50 (AM)
HIV-1/CEM HIV-2/CEMa HIV-2/CEM-TK
AZT-PPA23 0.055/ > 172 0.07 12
AZT23 0.005/>100 0.008 >100
d4T-PPA23 0.085/>100 0.102 0.075
d4T23 0.16/z 100 0.27 25
ddA-PPA24 0.016/2.57 0.35 –
ddA24 4/>100 8 –
d4A-PPA21 0.006/3.8 0.018 –
d4A21 20/91 20 –
3TC-PPA20 2.5/– 3.0 5.5 (65)b
3TC20 0.01/– 0.02 0.07 (30)b
ddisoA-PPA10,c 0.06/2.9 0.04 –
ddisoA10,c >425/>425 >425 –
araA-PPA25 >250/225 >250 –
araA25 >10/20 >10 –
a For cytotoxicity see HIV-1/CEM.
b HIV-2/CEM-dCK .
c MT-4 cells.
J. Zemlicka / Biochimica et Biophysica Acta 1587 (2002) 276–286278
tography has made possible for the first time to investigate
anti-HIV potency of pure diastereoisomers differing by con-
figuration at the phosphorus atom [28,29]. The Sp diaster-
eoisomer was about 10 times more potent than the Rp
counterpart. Similar differences in antiviral activity between
Rp and Sp diastereoisomers were noted in the case of cycloSal
pronucleotides [30,31]. One factor that was not previously
considered for explanation of these results is a different
behavior of stereoisomers in passage through chiral mem-
brane channels. In contrast, earlier experiments with partially
separated Rp and Sp diastereoisomers of moderately effective
hexyl phosphorovalinate isopropyl ester of AZT did not
indicate significant differences in anti-HIV activity [6].
An attempted activation of dinucleoside phosphates
derived from AZT and 3V-fluoro-3V-deoxythymidine (com-
pounds 12a–12d) by introducing a methyl alaninate func-
tion was not successful [32]. This is not surprising because
the rationale was based on a no longer tenable concept that
HIV protease might assist in hydrolysis of the PPA
prodrugs [6]. The AZT ‘‘pronucleotides’’ 12a and 12c
were about 30 to 40 times less potent against HIV-1 than
AZT alone. There was no significant difference between D-
and L-alanine derivatives in both pairs of analogues 12a,
12c and 12b, 12d indicating a similar type of cleavage of
the phosphodiester bond accompanied by release of some
AZT.
Combining SATE and PPA structures has led to mixed
PPA/SATE pronucleotides 13a that can be activated [33] by
two different mechanisms (Scheme 3). A comparison of
anti-HIV effects has shown that potency of 13a is slightly
higher than that of AZT-PPA. Interestingly, both a- and h-
alaninates 13a and 13b were almost equipotent (EC50 2.9
and 2.5 AM) whereas the corresponding phenyl phosphoro-
h-alaninate triester was inactive (see also Ref. [14]). This
indicates differences in mechanisms of phosphoramidate
cleavage of both types of pronucleotides although the SATE
function is preferentially attacked by esterase and the
delivery of monophosphate occurs via phosphoro-h-alani-
nate (see Section 5). Replacement of amino acid moiety
with simple amines led also to active pronucleotides [34].
The isopropylamidate 13c was the most potent (EC50 0.63
AM).
4. Antiviral activity of PPA triesters of ‘‘nonclassical’’
nucleoside analogues
4.1. Allenes and methylenecyclopropanes
It is clear from the results discussed above (Table 1) that
the most extensively studied PPA pronucleotides have been
derived from nucleoside mimics with a five-membered ring
(mostly furanose), e.g., AZT, d4T and 3TC. Acyclic ana-
logues were investigated only rarely [22]. In this chapter, an
application of the PPA pronucleotide approach to nucleoside
analogues, which do not possess a furanose moiety or an
Chart 1. Miscellaneous prodrugs based on PPA concept.
Table 2
Anti-HIV activity of phenyl phosphonic alaninates 11a and 11b derived
from PMEA and PMPA
Compound HIV-1/MT-4a (SI) HIV-2/M-T4a (SI) MT-4b
Phosphonate 11a 0.23 (22) 0.15 (34) 5.1
PMEA 7.0 (21) 7.5 (19) 144
Phosphonate 11b 0.029 (2462) 0.026 (2746) 71.4
PMPA 2.3 (86) 1.4 (141) 197
Selected data from Ref. [26].
a EC50 (AM).
b CC50 (AM).
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acyclic portion thereof, will be summarized. The list of
investigated structures is given in Chart 2. Three groups of
PPA pronucleotides are readily discerned. The first group
(compounds 14a and 14b) is derived from allenic analogues
[35,36] 14c and 14d; adenallene (14c) is an anti-HIV agent.
For comparison, SATE pronucleotide 14e was also included.
The second group (compounds 15a–15e) is related to (Z)-
methylenecyclopropane analogues [37] (15f–15j), which
have a broad antiviral selectivity. The structures of the third
group of PPA pronucleotides are more diversified and
include (E)-methylenecyclopropane pronucleotide 16a
(parent analogue 16b) as well as unsaturated derivatives
17a–19a (parent analogues 17b–19b). A common feature
of parent analogues in this group is a lack of significant
antiviral potency. Finally, spiropentane pronucleotide 20a
derived from a moderately active anti-HCMVagent 20b was
also examined.
Conversion of racemic or (R)-adenallene—14c or (R)-
14c—to PPA pronucleotides 14a and (‘‘R’’)-14a did indeed
increase the anti-HIV-1 activity [11] in ATH-8 cells but at an
expense of increased cytotoxicity and overall selectivity
index (SI) was lower than that of adenallene 14c or (R)-
14c (Table 3). This is probably caused by an elevated
intracellular level of adenallene phosphates which could
then interact with cellular DNA polymerases. Comparison
of anti-HIV-1 potency of PPA and SATE pronucleotides 14a
and 14e in three different assays [38] has indicated that the
former prodrugs are more potent and they exhibit a more
favorable SI (Table 4). It is possible that intracellular
phosphodiesterase, which is necessary in the process of
activation [3] of SATE pronucleotides, is unable to effi-
ciently cleave phosphodiester intermediate arising during
activation of allenic pronucleotide 14e. Although anti-HIV
activity of adenallene (14c) parallells that of ddA and ddI
Chart 2. Pronucleotides of ‘‘nonclassical’’ antiviral nucleotide analogues.
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[35], the corresponding hypoxallene analogue 14d and PPA
prodrug 14b had little anti-HIV activity [11]. The activation
mechanism, initiated by phosphorylation [39] which is
available to ddI (conversion to ddA monophosphate) is then
inoperative in the case of hypoxallene (14d) or the corre-
sponding monophosphate generated from 14b.
Investigation of PPA pronucleotides of methylenecyclo-
propane analogues was performed in several viral assays
and permitted to draw some conclusions about the struc-
ture–activity relationships. From prodrugs 15a–15e listed
in Chart 1, adenine and 2,6-diaminopurine pronucleotides
[13,40] 15a and 15c were the most potent against HIV-1 in
three assays (Table 5). Although they were more toxic, their
SI values surpassed that of parent compounds 15f and 15h.
Especially effective was the 2,6-diaminopurine analogue
15c. Interestingly, active PPA prodrug 16a was also
obtained from inactive E-analogue 16b. Both pronucleotides
15a and 15c were also active [40] against a clinical HIV-1
isolate in PHA–PBM cells. They were about 10 times less
active against HIV-2 than HIV-1 [40] (Table 6). Because
most of the non-nucleoside reverse transcriptase inhibitors
(NNRTIs) are effective only against HIV-1 (see Ref. [41] for
an exception), this result has indicated that 15a and 15c act
as nucleoside reverse transcriptase inhibitors (NRTIs) or
their phosphorylated metabolites. Pronucleotides 15a and
15c derived from racemic analogues 15f and 15h are
mixtures of four diastereoisomers. Anti-HIV activity of
diastereoisomers 15c obtained from enantiomers of 15h (2
diastereoisomers from each enantiomer) indicated that both
are effective against HIV-1 albeit the (‘‘R’’)-15c was about
six times more potent than (‘‘S’’)-15c [42]. Guanine pronu-
cleotide 15b and the parent analogue 15g were inactive.
Sensitivity of pronucleotides 15a and 15c toward HIV-1
strains resistant to AZT, ddI and multiple NRTIs was also
investigated [40]. No cross-resistance of 15a and 15c with
any of these strains was observed (Table 7) as judged from
the EC50 values compared with a wild type of HIV-1. As a
continuation of these studies, an HIV-1P16 variant resistant
to most effective pronucleotide 15c was selected [43]. The
variant exhibited cross-resistance to 3TC but not AZT or ddI
(Table 8). It was also less sensitive to pronucleotide 15a.
Nevertheless, initial mutation M184 from Met to Ileu
persisted after 16 passages and it did not change to Val as
observed with 3TC. Further investigation has indicated that
HIV-1M148I and HIV148V variants [43] resistant to 3TC are
sensitive to AZT and ddI. Resistance to pronucleotides 15a
and 15c is approximately 50–70 times lower than to 3TC
(Table 9). There is little structural similarity between 3TC
and pronucleotide 15c except the diaminopyrimidine por-
tion of the base which resembles the cytosine ring of 3TC.
Molecular modeling studies of a ‘‘stalled’’ complex of 3TC
triphosphate with reverse transcriptase (RT) indicate that
oxathiolane portion interacts with Ileu or Val [44] of
mutated enzyme. Such interaction may be sterically less
demanding in a more compact methylenecyclopropane
triphosphate generated from 15c. At any rate, studies of
diastereoisomers (‘‘R’’)-15c and (‘‘S’’)-15c are necessary to
clarify the mechanism of resistance.
Pronucleotides 15a, 15c and 16a were significantly
more effective against HBV in vitro [13] than parent
analogues 15f, 15h and 16b (Table 10). The activity pattern
followed that found in HIV assays (Table 5). Again, the
Table 4
Comparison of anti-HIV activity of PPA and SATE pronucleotides of
adenallene 14a and 14e [38]
Compound EC50/CC50 (AM)a
HIV-1/IIIB HIV-1/LAI
CEM-SS MT-4 MT-2
14a 0.35/44 (126) 0.4/7.5 (19) 0.41/5 (12)
14e 1.2/>10 (>8.3) 8.9/>10 (>1.1) 6.4/28 (4.4)
a The SI values are in parentheses.
Table 5
Inhibition of HIV-1 replication by phosphoralaninate prodrugs of Z- and E-
methylenecyclopropane analogues 15a, 15b, 15c, 16a and parent analogues
15f, 15g, 15h, 16b
Compound EC50/CC50 (AM)a
HIVIIIB RT
b HIVLAI
CEM-SS MT-2c MT-2d
15a 0.05/1.1 (22) 0.0026/0.24 (92) 0.0022
15f 20/>100 (>5) 0.75/32 (43) 0.54
15b >100/>100 >76/76 –
15g >100/>100 >70/70 –
15c 0.2/38 (190) 0.034/21 (618) 0.0038
15h >100/>100 12/>100 (>8) 4.1
16a 1.3/66 (51) 0.66/24 (6) 0.51
16b >100/>100 >100/>100 not tested
Selected data from Refs. [13,40].
a The SI values are in parentheses.
b Reverse transcriptase (RT) activity assay.
c Cytopathic effect (CPE) assay.
d Inhibition of p24 Gag protein production.
Table 6
Comparison of activity of PPA pronucleotides 15a and 15c against HIV-2
and HIV-1
Compound EC50 (AM)
HIV-2ROD/MT-2 HIV-1LAI/MT-2
15a 0.03 0.002
15c 0.38 0.038
Data from Ref. [40].
Table 3
Anti-HIV activity of PPA pronucleotides of adenallenea 14a
Compound EC50/CC50 (AM) SI
14a 0.88/2.1 2.4
Adenallene (14c) 14/>100 >7.1
(‘‘R’’)-14a 0.21/3 14
(R)-Adenallene [(R)-14c] 5.8/>200 >35
Selected data from Ref. [11].
a HIV-1/ATH8.
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2,6-diaminopurine pronucleotide 15c has the most favor-
able SI. Importantly, it has also little long-term toxicity
measured as inhibition of mitochondrial DNA synthesis.
Anti-HBV activity of diastereoisomers 15c obtained from
enantiomers of 15h exhibited a trend reversed from that
found in HIV assays; the (‘‘S’’)-15c was about twice as
potent as (‘‘R’’)-15c [42]. A strong anti-HIV and anti-HBV
potency of PPA pronucleotides 15a and 15c (Tables 5 and
10) was not duplicated in prodrugs 15d and 15e, which
were equally or more active but also cytotoxic. Only
guanine pronucleotide 15b was five times more effective
than the parent analogue 15g and noncytotoxic. Conse-
quently, circumvention of the first phosphorylation step
(Scheme 1) provided little benefit.
Against HCMV and murine cytomegalovirus (MCMV),
all parent analogues 15f–15j were active [45,46] and,
therefore, it was of interest to study the respective PPA
pronucleotides 15a–15e (Table 11). The antiviral potency of
pronucleotides remained roughly the same [13] and any
increases were accompanied by an elevated cytotoxicity (see
15a and 15e). Interestingly, a slightly improved activity
without cytotoxic effect was noted with 2,6-diamino pronu-
cleotide 15c but guanine analogue 15b was less potent than
the parent compound 15g. Potency of 2,6-diaminopurine
pronucleotide 15c, which was effective against HIV and
HBV (Tables 5 and 10), was increased only two to six times
over that of 15h and it decreased in MCMV assay. Interest-
ingly, the cytotoxicity effects observed in human (HFF)
culture were absent in murine (MEF) cells throughout this
series of pronucleotides. The diastereoselectivity—(‘‘S’’)-
15c was more potent than (‘‘R’’)-15c—[42] followed S
enantioselectivity pattern observed in purine methylenecy-
clopropane nucleoside analogues 15f–15j.
The results with other herpesviruses followed a similar
trend. Parent analogues 15f–15j are only poor inhibitors of
replication of HSV-1 and HSV-2 [45,46]. The antiviral
activity was increased in all tested pronucleotides [13]
except guanine PPA prodrug 15b (Table 12), which was
inactive and noncytotoxic. Cytotoxicity increases were
apparent with other pronucleotides.
The activity of parent analogues 15f–15j against
Epstein–Barr virus (EBV) (Table 13) is similar to that of
observed in anti-HCMV assays (Table 11) [45,46]. A
comparison of pronucleotide effects is then of interest.
Introduction of PPA grouping into parent analogues
increased significantly the anti-EBV potency in both H-1
and Daudi cells only in a single case of pronucleotide 15e.
This effect was accompanied by cytotoxicity. Overall, the
Table 8
Sensitivity of the strain HIV-1P16 resistant to PPA pronucleotide 15c toward
anti-HIV agents
Compound EC50 (AM) CC50 (AM)
HIV-1LAI HIV-1P16 MT-2
15a 0.012 >0.49 (>41) 0.49
15c 0.047 4.9 (104) 28
AZT 0.028 0.02 (1) >100
ddI 3.9 5.7 (2) 59
3TC 0.91 >1000 (>1100) –
The fold differences relative to HIV-1LAI are given in parentheses.
Adapted from Ref. [43].
Table 9
Sensitivity of infectious HIV-1 reverse transcriptase mutants to PPA
pronucleotides 15a and 15c and other anti-HIV agents
Compound EC50 (AM) CC50 (AM)
HIV-1wt HIV-1M141I HIV-1M184V
15a 0.026 0.24 (9) 0.3 (12) 0.52
15c 0.29 2.6 (9) 3.1 (11) 23
AZT 0.04 0.008 (0.2) 0.006 (0.15) >100
ddI 3.0 2.3 (0.8) 4.5 (2) 61
3TC 1.7 >1000 (>590) >1000 (>590) >1000
The fold differences relative to HIV-1wt are given in parentheses.
Adapted from Ref. [43].
Table 10
Inhibition of replication of HBV by PPA pronucleotides 15a, 15b, 15c, 15d,
15e, 16a and parent analogues 15f, 15g, 15h, 15i, 15j, 16b
Compound EC50/CC50 (AM)
HBV/2.2.15 mtDNAa
15a 0.01/0.3 (30)b –
15f 2/>100c –
15b 2/>100c
15g 10/>100c
15c 0.08/45 (564)b >50
15h 10/>100c –
15d 2/9c –
15i 2/>100c –
15e 2/2.2c –
15j >10/>100c –
16a 1.2/4.5 –
16b >10/>100c –
ddC 1.4 0.07
Selected data from Ref. [13].
a IC50 (AM) of inhibition of mitochondrial (mt) DNA synthesis in CEM
cells.
b Selectivity index (SI).
c Cytotoxicity was determined in CEM cells.
Table 7
Activity of PPA pronucleotides 15a and 15c against wild-type and drug-
resistant infectious HIV-1
Compound EC50 (AM)a
HIV-1wt HIV-1215 HIV-174 HIV-162/75/77/116/151
15a 0.029 0.03 0.013 0.037
15c 0.36 0.30 0.39 0.39
AZT 0.017 0.14 0.013 11
ddI 3.7 4.2 25.4 47
HIV-1wt =wild-type, HIV-1215 =AZT-resistant, HIV74 = ddI-resistant, HIV-
162/75/77/116/151 =multiple ddN-resistant strain of HIV-1.
Adapted from Ref. [40].
a MT-2 cells, p24 Gag protein was determined by radioimmunoassay.
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effect of PPA pronucleotides seems to be less pronounced
than in HCMV assays. Stronger assay variations (H-1 vs.
Daudi) are also typical. For example, pronucleotide 15a was
cytotoxic only in H-1 cells. The ‘‘R’’ and ‘‘S’’ diaster-
eoisomers of 15c exhibited a varying assay-dependent
stereoselectivity against EBV as observed with the enan-
tiomers of parent analogue 15h [42].
Anti-VZV activity can be, to some extent, compared to
HSV-1 and HSV-2 results (Table 12). Parent analogues 15f–
15j lack, with the exception of 15f, any significant potency
against VZV in HFF cells (Table 13). Adenine analogue 15f
was the only one whose activity was not substantially
increased after transformation to pronucleotide 15a. In other
cases, quite substantial increases of activity were observed
pointing to importance of the first phosphorylation step
(Scheme 1). The SI of 15c, 15d and 15e was significantly
increased over the parent analogues, a trend not seen in
other herpesvirus assays (Tables 11–13). The diaster-
eoisomer ‘‘S’’-15c was three times more active than ‘‘R’’-
15c [42].
Parent analogues 15h–15j can be considered as potential
precursors of guanine derivative 15g [13]. Nevertheless,
guanine pronucleotide 15b showed lesser activity than 2,6-
diaminopurine prodrug 15c in almost all assays and, most
notably, against HIV (Table 5). This supports a hypothesis
that antiviral potency of 15c is not dependent on intra-
cellular conversion to phosphorylated intermediates resul-
tant from guanine analogue 15g. It is possible that 2,6-
diaminopurine pronucleotide 15c is an analogue of adenine
prodrug 15a. Although the results with pronucleotides 15d
and 15e are less clear-cut, evidence from several assays
suggests that their antiviral effects do not require trans-
formation to phosphorylated metabolites of 15g. Alternately,
guanine pronucleotide 15b may not penetrate the cellular
membrane as easily as the more lipophilic prodrugs 15a and
15c–15e, which are then converted to phosphates of 15g. In
addition, a weak substrate efficiency of phosphoramidate
intermediates for phosphoamidase, an enzyme important for
metabolism of PPA pronucleotides (see Section 5), may also
hamper the antiviral potency of 15b. Interestingly, ACV-
PPA, a guanine derivative, is likewise a poor antiviral agent
[22]. Further studies are clearly needed to clarify all these
aspects.
Although PPA pronucleotides of nucleoside analogues,
particularly of AZT and d4T, were subjects of many studies
(see Section 3) data on in vivo activity have been scarce
[18]. In one instance [47], mice infected with MCMV were
treated orally with 2-amino-6-methoxypurine pronucleotide
15e (Table 14). The results were almost identical with those
obtained for a ganciclovir control at both tested levels (40
and 10 mg/kg) and no toxicity was observed. Equally,
cytotoxicity was absent in in vitro assay of pronucleotide
15e against MCMV as contrasted with HCMV (Table 11).
Therefore, prodrug 15e may not be a drug candidate of
choice against HCMV but the results indicate that PPA
Table 12
Inhibition of HSV-1 and HSV-2 replication by PPA pronucleotides and
parent methylenecyclopropane analogues
B EC50/CC50 (AM) CC50 (AM)
HSV-1 HSV-2 KB
BSC-1a Verob
15a 2.5 >1/1 >1/1 0.5
15f 26 28/>100 59/>100 78
15b >100 >100/>100 >100/>100 >100
15g >100 >100/>100 >100/>100 >100
15c 50 30/35 15/35 40
15h >100 >100/>100 >100/>100 >100
15d 5 0.9/9 1.8/9 65
15i 15 31/>100 41/>100 >100
15e 2 0.6/2.2 0.6/2.2 80
15j 33 >50/>100 >50/>100 >100
Selected data from Ref. [13].
a ELISA (enzyme-linked immunosorption assay). For cytotoxicity see
KB cells.
b Plaque reduction assay. Cytotoxicity was determined in CEM cells.
Table 13
Inhibition of EBV and VZV replication by PPA pronucleotides and parent
methylenecyclopropane analogues
Compound EC50/CC50 (AM)
EBV/H-1 EBV/Daudi VZV/HFF
15a 0.1/1a 1.0/>108 7.6/4.3
15f 0.2/>50 3.2/368 2.5/>429
15b >10/>50 0.31/>103 8.1/>206
15g 0.3/>50 5.6/>214 61/279
15c 5.5/35a 3.8/26 1.0/121
15h 1.5/>50 6.9/>215 93/266
15d 10/23 2.3/19 0.64/126
15i 4/>100a 12/>184 13/327
15e 0.4/4.6 0.75/4.4 0.12/34
15j 1.6/>50 18/>202 24/404
Selected data from Ref. [13].
a Cytotoxicity was determined in CEM cells.
Table 11
Inhibition of HCMV and MCMV replication by PPA pronucleotides and
parent methylenecyclopropane analogues
Compound EC50/CC50 (AM)
HCMV/HFF MCMV/MEF
Townea AD 169b
15a 0.14/2.5 not tested not tested
15f 2.1/>100 – –
15b 4.2/>100 25/>206 3.3/>206
15g 2.1//>100 1.2/>429 0.3/>429
15c 4/>100 7.8/121 3.2/211
15h 24/>100 16/266 0.6/293
15d 0.25/10 6.2/126 0.94/101
15i 0.4/>100 2.4/327 0.37/220
15e 0.16/3.7 4.5/34 0.24/126
15j 3.1/>100 5.3/>404 0.4/261
Selected data from Ref. [13].
a Visual cytotoxicity.
b Cytotoxicity by neutral red dye uptake.
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pronucleotides can be effective in vivo without adverse
toxicity. The results with 15e also indicate that phenol
[18] released from PPA pronucleotides in the process of
activation (see Section 5) does not cause toxicity, at least in
mice.
4.2. Other nucleoside analogues lacking the carbohydrate
moiety
It was of interest to extend the PPA pronucleotide
concept to other analogues whose structures are distant
from a ‘‘classic’’ ribofuranose form of nucleosides. Four
types of such prodrugs (17a–20a), which were all derived
from inactive or moderately active parent compounds (17b–
20b, Chart 2) were investigated. The focus of pronucleo-
tides 17a–19a was on anti-HIV activity [11,12] whereas a
more comprehensive antiviral study was performed [48]
with spiropentane prodrug 20a. Pronucleotide of cis-butenol
analogue 17a was effective against HIV-1 in ATH-8 cell
submicromolar level with a low cytotoxicity (EC50/CC50
0.5/100 AM). By contrast, the trans isomer 18a was inactive
but it was cytotoxic (CC50 1 AM) [12]. Acetylenic com-
pound 19a was inactive and noncytotoxic [11]. Pronucleo-
tide 20a whose parent analogue 20b is only moderately
effective against HCMV was active [48] against HCMV in
HFF cells (Table 15) without cytotoxicity. Inhibition of
replication of EBV, HIV-1 and HBV in micromolar range
was also noted although accompanied by a varying degree
of cytotoxicity. Prodrug 20a was only moderately effective
against HSV-1 and HSV-2.
The results with 17a and 20a along with the results
obtained with allenic and methylenecyclopropane pronu-
cleotides (Section 4.B) show that a wide range of nucleoside
analogues can be activated by a PPA pronucleotide ap-
proach.
5. Mechanism of action of PPA pronucleotides
The mode of action of PPA pronucleotides is shown in
Scheme 4. The matter is a subject of current intense
investigation and more refinements of this mechanism are
to be expected. As in the case of SATE pronucleotides [3],
the alanine ester group of PPA pronucleotide is first hydro-
lyzed by an intracellular esterase to give intermediate 21.
Pig liver esterase (PLE) has been widely used as a model of
intracellular enzyme(s) [11,12,48,49,50] but, recently,
esterase(s) capable of hydrolyzing PPA pronucleotides were
detected in cellular extracts and serum [51]. It was sug-
gested that PLE-catalyzed hydrolysis can be used as a
predictor for anti-HIV activity of PPA pronucleotides and
related analogues [8]. Nevertheless, other studies have
indicated that this activity is just one of several factors
determining the antiviral efficacy of PPA prodrugs [11,12,
51–53].
The esterase step is followed by an intramolecular dis-
placement of the phenoxy group by the carboxylate anion of
intermediate 21 to form a five-membered ring mixed anhy-
dride 22. The ease of cyclization depends on the structure of
the analogue. Thus, cyclization of intermediate 21 derived
from AZT is more difficult than that of d4T [51]. In case of
h-alaninate pronucleotide, the esterase-catalyzed hydrolysis
stops after the first step and no cyclic anhydride with a six-
membered ring is formed [33,51].
In the next step, anhydride 22 suffers a hydrolysis which
is not enzyme-assisted to give phosphoralaninate 23.
Because possibility of a P–N bond cleavage was ruled
out [50], hydrolysis can only proceed by an attack A at
the carbonyl group of 22 or attack B at the phosphate
portion. Usually, hydrolysis or methanolysis of mixed
Table 14
Effect of oral treatment with pronucleotide 15e on the mortality of Balb/c
mice inoculated with MCMV
Treatment Mortality
Number Percent P-value MDDa P-value
Pronucleotide 15e
Placebo–0.4% CMCb 13/15 87 – 6 –
40 mg/kg 1/15 7 < 0.0001 6 NSc
40 mg/kg-toxicityd 0/10 0 – – –
10 mg/kg 8/15 53 NS 5 NSc
10 mg/kg-toxicityd 0/10 0 – – –
Ganciclovir
Placebo–water 14/15 93 – 6 –
40 mg/kg 2/15 13 < 0.0001 10 NSc
10 mg/kg 7/15 47 < 0.05 7 NSc
Animals were treated twice daily for 5 days beginning 24 h after viral
inoculation.
Adapted from Ref. [47].
a MDD, mean day of death.
b CMC, carboxymethyl cellulose.
c NS, not statistically significant when compared to placebo control.
d Uninfected animals.
Table 15
Antiviral activity of phosphoralaninate prodrug of medial-syn spiropentane
analogue of 2V-deoxyadenosine 20a and parent analogue 20b
Compounda HCMV HSV-1 HSV-2
HFFb BSC-1c Verob,d Verob,d
20a 0.38/100 7.0/70 20/27 31/27
20b 20/100 70/>100 >50/>100 >50/>100
Compounda EBV HIV-1e HBV
Daudi CEM-SS 2.2.15
20a 2.8/7.6 3.5/32 3.1/27d
20b 22/202 >100/>100 >10/>100d
Selected data from Ref. [48].
a EC50 /CC50 (AM).
b Plaque reduction.
c ELISA.
d Cytotoxicity was determined in CEM cells.
e Reverse transcriptase assay.
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carboxylic and phosphoric anhydrides [54] proceeds by
attack A, but in the case of five-membered ring anhydrides
attack B can prevail [55,56]. The mode of hydrolysis of
intermediate 22 then remains to be established.
Phosphoralaninate 23 was the final product of PLE-
catalyzed hydrolysis of a number of PPA pronucleotides
of different structure [11,12,48–50]. It was shown that
product 23 can be accumulated inside the cells and serve
as a depository form of the respective monophosphate [49].
Interestingly, d4T phosphoralaninate 23 exhibited anti-HIV
effect comparable to d4T [49] but a similar derivative of
adenallene (14c) was inactive [12]. The latter more polar
analogue may be less penetrable through the cellular mem-
brane. Adenallene phosphoralaninate 23 also did not inhibit
HIV-RT.
Although it was suggested earlier that the last activation
step, conversion of phosphoralaninate 23 to monophosphate
2, is catalyzed by intracellular phosphoamidase [11,49], a
direct evidence has been missing. More recently, a purified
enzyme obtained from rat liver was capable of converting
intermediates 23 derived from AZT-PPA and d4T-PPA to
the corresponding monophosphates 2 [51]. The substrate
efficiency can vary substantially. Thus, AZT phosphorala-
ninate 23 is less readily hydrolyzed than the d4T derivative
[51]. However, phosphoamidase is apparently capable of
hydrolyzing substrates of a wide range of structures, e.g.,
phosphoralaninates 23 of isoddA [10], allenic [11], spiro-
pentane [48], methylenecyclopropane [13] and other unsa-
turated analogues [12], as judged from antiviral activity of
the corresponding PPA pronucleotides. It was suggested
earlier [50] that intermediates 23 can also be converted to
monophosphates by the action of phosphodiesterase. Such a
proposal seemed at variance with a report [57] that phenyl-
alanyl analogue of intermediate 23 derived from thymidine
was a product of cleavage of the corresponding oligonu-
cleotide by snake venom phosphodiesterase. This indicated
that P–N bond in 23 was resistant to the action of latter
enzyme. Also, phosphoramidate 23 resultant from adenal-
lene PPA (14a) was not cleaved by snake venom phospho-
diesterase [11]. However, according to more recent findings,
phosphoralaninates 23 derived from AZT and d4T were
degraded [51]. At any rate, it is not clear whether a
mammalian phosphodiesterase (5V-exonuclease) can effec-
tively cleave intermediates of type 23.
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